Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Sinema has backed a bill advancing in the Arizona legislature that would include a $5 million grant to a neurological ...

Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had a ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing ...

Midi Health, the virtual care company best known for providing hormone therapy for women in menopause, is expanding to ...

Eisai and Merck succeeded in stopping Shilpa Medicare Ltd. from launching a generic version of Lenvima for at least another ...

Oric Pharmaceuticals raises $125M for Phase 3 prostate cancer drug ORIC-944 after positive early results, with study planned ...